Royalty PharmaSTU:RPD +0.52%72 Dividend Yield % is 1.63% as of Jun. 26, 2026, which is 23% below its 10-year median of 2.13. GuruFocus rates STU:RPD with a GF Score™ of 72/100 and a GF Value™ of €32.95 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 151 Biotechnology companies, Royalty Pharma ranks better than 52.98% on this metric.
As of today (2026-06-26), the Trailing Annual Dividend Yield of Royalty Pharma is 1.63%.
Warning Sign:
Royalty Pharma PLC stock Dividend Yield % is close to 5-year low.
The historical rank and industry rank for Royalty Pharma's Dividend Yield % or its related term are showing as below:
STU:RPD'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.31 Med: 2.13 Max: 3.34
Current: 1.63
During the past 9 years, the highest Dividend Yield of Royalty Pharma was 3.34%. The lowest was 0.31%. And the median was 2.13%.
STU:RPD's Dividend Yield % is ranked better than 52.98% of 151
companies
in the Biotechnology industry
Industry Median: 1.53
vs STU:RPD: 1.63
During the past 12 months, Royalty Pharma's average Dividends Per Share Growth Rate was 5.30% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 5.00% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 18.90% per year.
During the past 9 years, the highest 3-Year average Dividends Per Share Growth Rate of Royalty Pharma was 38.70% per year. The lowest was 5.00% per year. And the median was 7.30% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Royalty Pharma's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:RPD vs BNTX, INSM, ROIV: Dividend Yield % Comparison
For the Biotechnology subindustry, Royalty Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Royalty Pharma Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 0.235000
2026-05-15
2026-05-15
2026-06-10
Cash Dividend
quarterly
USD:EUR 0.856000
USD 0.235000
2026-02-20
2026-02-20
2026-03-10
Cash Dividend
quarterly
USD:EUR 0.846000
USD 0.220000
2025-11-14
2025-11-14
2025-12-10
Cash Dividend
quarterly
USD:EUR 0.865000
USD 0.220000
2025-08-15
2025-08-15
2025-09-10
Cash Dividend
quarterly
USD:EUR 0.859000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Royalty Pharma's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield
=
Most Recent Full Year Dividend
/
Current Share Price
=
0.77925
/
48.025
=
1.62 %
Current Share Price is €48.025. Royalty Pharma's Dividends per Share for the trailing twelve months (TTM) ended in Today is €0.77925.
Royalty Pharma's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
0.80464
/
48.025
=
1.68 %
Current Share Price is €48.025. Royalty Pharma's Dividends per Share for the forward twelve months is calculated as €0.20116 * 4 = €0.80464.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (STU:RPD) has a Dividend Yield % of 1.63% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Royalty Pharma and its competitors. This is 23% below median its historical median of 2.13. Over the past decade, Royalty Pharma's Dividend Yield % has ranged from 0.31 to 3.34. According to the industry distribution chart, Royalty Pharma ranks #71 out of 151 companies in the Biotechnology industry, placing it in the top 47%.
Is Royalty Pharma's Dividend Yield % too high?
Royalty Pharma's current Dividend Yield % of 1.63% is 23% below median its 10-year median of 2.13. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 3.34. The Biotechnology industry median Dividend Yield % is 1.53. Royalty Pharma's value of 1.63% is 6.5% above this industry median. Based on the distribution chart, Royalty Pharma ranks #71 out of 151 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Royalty Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Dividend Yield % compare to BNTX and INSM?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #71 out of 151 companies for Dividend Yield %. This puts Royalty Pharma in the upper half of its industry. The industry median Dividend Yield % is 1.53. Royalty Pharma's value of 1.63% is 6.5% above this benchmark. Historically, Royalty Pharma's own Dividend Yield % has ranged from 0.31 to 3.34 over the past decade. While the company's 10-year median is 2.13 vs. the industry median of 1.53, Royalty Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.53, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Royalty Pharma's current Dividend Yield % of 1.63% is 6.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Royalty Pharma and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Royalty Pharma's current Dividend Yield % is 1.63%, which is 23% below median its own 10-year median of 2.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (STU:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €32.95, compared to a current price of €48.03 — trading 45.8% above its estimated fair value. The current Dividend Yield % is 1.63%, which is 23% below median its 10-year median of 2.13 and 6.5% above the Biotechnology industry median of 1.53. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Royalty Pharma (STU:RPD), the current Dividend Yield % is 1.63% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (STU:RPD) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of €48.03 is trading 45.8% above its estimated GF Value™ of €32.95.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for STU:RPD:
Dividend Yield %: 1.63% (23% below median its 10-year median of 2.13)
GF Value™: €32.95 vs. price of €48.03 (45.8% above fair value)
Industry Position: 6.5% above the Biotechnology median (#71 of 151)
No single metric tells the full story. See the STU:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score
Get the complete analysis for STU:RPD
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RPD has been successfully added to your 
